

- patients on continuous venovenous haemofiltration: A prospective randomized multicentre trial. *Nephrol Dial Transplant*. 2011; **26**:232–239.
- 25 Shum HP, Chan KC, Yan WW. Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismatic citrate 10/2 solution. *Ther Apher Dial*. 2012; **16**:81–86.
- 26 Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. *Clin J Am Soc Nephrol*. 2006; **1**:79–87.
- 27 Bugg NC, Jones JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. *Anaesthesia*. 1998; **53**:895–902.
- 28 Link A, Klingele M, Speer T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. *Crit Care*. 2012; **16**:R97.

---

## Heparin-induced thrombocytopenia in a hemodialysis patient treated with fondaparinux: Nephrologists between two fires

Yalcin SOLAK,<sup>1</sup> Sinan DEMIRCIOGLU,<sup>2</sup> Ilker POLAT,<sup>2</sup> Zeynep BIYIK,<sup>1</sup> Abduzhappar GAIPOV,<sup>1</sup> Kadir ACAR,<sup>3</sup> Suleyman TURK<sup>1</sup>

<sup>1</sup>Division of Nephrology, Department of Internal Medicine, Meram School of Medicine, Konya University, Konya, Turkey; <sup>2</sup>Department of Internal Medicine, Meram School of Medicine, Konya University, Konya, Turkey; <sup>3</sup>Division of Hematology, Department of Internal Medicine, Meram School of Medicine, Konya University, Konya, Turkey

### Abstract

Heparin-induced thrombocytopenia (HIT) is caused by heparin exposure and presents with reduced platelet count. Patients undergoing hemodialysis (HD) treatment have increased risk of developing HIT due to prolonged exposure to unfractionated heparin or low-molecular weight heparin. We report a 79-year-old male patient with end-stage renal disease who developed type-II HIT during maintenance HD. Platelet count of the patient decreased gradually and antiplatelet factor IV antibody was found to be positive. The patient was treated with fondaparinux and continued heparin-free HD. Unfortunately, despite favorable initial response without any thrombotic episodes, the patient died due to severe sepsis complicated by gastrointestinal hemorrhage.

**Key words:** Heparin-induced thrombocytopenia, hemodialysis, fondaparinux, platelets

---

### INTRODUCTION

Heparin-induced thrombocytopenia (HIT) is defined as a decrease in platelet count during or shortly following

exposure to heparin.<sup>1</sup> In vivo heparin binds to platelet factor 4 (PF4), a heparin-neutralizing protein released from activated platelets.<sup>2</sup> In some patients, the heparin-PF4 complex triggers an immune response that results in the production of an antibody.<sup>3</sup> Two different types of HIT are recognized: type I is a benign form not associated with an increased risk of thrombosis. This form approximately affects 10% of patients treated with heparin and is

---

Correspondence to: Y. Solak, MD, Konya Universitesi, Meram Tıp Fakültesi, Hemodiyaliz Sekreterliği, Meram, Konya 42080, Turkey. E-mail: yalcinsolakmd@gmail.com

characterized by a mild and transient thrombocytopenia (platelet count is rarely below  $100 \times 10^3/\text{mm}^3$ ).<sup>4</sup> HIT type II is immune mediated and associated with a risk of thrombosis.

Diagnosis of HIT requires consideration of both clinical likelihood and laboratory data. The patient with HIT has a recent history or current treatment with standard heparin or low-molecular weight heparin (LMWH). Other apparent causes of low platelet counts should be excluded. Finally, detection of the presence of antibodies that bind to heparin-PF4 complexes by immunoassays confirms the diagnosis. Prompt recognition and appropriate treatment are keys to prevent thrombosis associated with HIT.

Mainstay of treatment is withholding further doses of unfractionated heparin (UFH) or LMWH and prevention of thrombosis development. To this end, currently three nonheparin anticoagulants that do not cross-react with HIT antibodies, danaparoid, lepirudin, and argatroban, are available for alternative anticoagulation in HIT.<sup>5,6</sup>

A synthetic pentasaccharide, fondaparinux, does not cross-react with HIT antibodies, thus this drug has been used successfully to prevent HIT-related thrombosis.<sup>7,8</sup>

Hemodialysis (HD) patients are regularly administered with heparin to prevent catheter and dialysis tubing system thrombosis. Thus, patients on maintenance HD have a risk of developing HIT due to prolonged exposure to UFH or LMWH.<sup>9</sup> Treatment of HIT in HD patients is similar to those of patients not on HD. There are only three case reports describing use of fondaparinux in HD patients.<sup>10,11</sup>

Here, we report a HD patient who developed type-II HIT and successfully treated with fondaparinux.


## CASE REPORT

We admitted a 79-year-old male patient with increasing uremic symptoms and hypervolemia. The patient had had metastatic prostate cancer, for which he had undergone transurethral resection operation. He also had chronic kidney disease due to obstructive uropathy. At admission he had bilateral 3+ pedal edema, presacral edema, and bilateral crackles at lung bases. His blood pressure was 130/80. Heart auscultation revealed an S3 and tachycardia without any murmurs. Other aspects of physical examination were unremarkable. Laboratory data at presentation were as follows: urea: 176 mg/dL, creatinine: 5.8 mg/dL, sodium: 136.7 mEq/L, potassium: 4.70 mEq/L, calcium: 8.1 mg/dL, phosphorus: 5.4 mg/dL, ESR: 45 mm/h, CRP: 119 mg/L, AST: 53 u/L, ALT: 20 u/L, albumin: 3.4 g/dL, total protein: 6.4 g/dL, hemoglobin: 9.4 g/dL, platelet count:  $394 \times 10^3/\text{mm}^3$ , WBC count:  $8.8 \times 10^3/$

$\text{mm}^3$ . Coagulation parameters were as follows: INR: 1.5, PT: 17.9 seconds, aPPT: 27.2 seconds. We placed an internal jugular vein central catheter and initiated intermittent HD with UFH. The symptoms of the patient lessened; however, he developed fever at the 10th day of his hospitalization, for which he was administered cefoperazone + sulbactam. The platelet count of the patient decreased gradually up to  $34 \times 10^3/\text{mm}^3$ . Peripheral smear confirmed thrombocytopenia excluding other causes. There were no fragmented erythrocytes. Coagulation parameters were within normal values during the course of thrombocytopenia. Antiplatelet factor IV antibody was found to be positive. With diagnosis of HIT type II, we changed HD anticoagulation order to saline rinse without any UFH or LMWH use. We also used heparin-free catheter lock solution. We monitored platelet counts of the patient and administered fondaparinux since other preparations, namely danaparoid, lepirudin, and argatroban, were not available in our country at that time. We used fondaparinux at a dose of 1.5 mg/day because of diminished renal function of the patient. We could not identify any origin for the high fevers even after multiple blood and urine cultures and change of the central venous catheter. There was no vegetation in the heart valves on transthoracic echocardiogram. Platelet counts gradually increased under this treatment up to  $116 \times 10^3/\text{mm}^3$  without any thrombotic episodes (Figure 1). But on the 70th day of hospitalization the patient developed sepsis. He was administered imipenem and vancomycin. Platelet counts decreased after sepsis. During the course of the hospitalization, he developed upper gastrointestinal bleeding presented with melena and hypotension. Because of hemodynamic instability, he was transferred to medical intensive care unit (ICU) where he was resuscitated with packed red blood cell suspensions and crystalloids. Fondaparinux was discontinued. The platelet count was between  $40$  and  $60 \times 10^3/\text{mm}^3$  during the course of ICU stay. Coagulation parameters were INR: 1.4, PT: 17.1 seconds, aPPT: 38.0 seconds. The patient died on the 80th day of hospitalization due to septic shock complicated by upper gastrointestinal bleeding.

## DISCUSSION

Owing to protracted exposure to heparin via both during intermittent HD sessions and catheter lock solutions, HD patients are at risk of developing HIT. A UK survey on HIT reported an incidence of 1.6%.<sup>12</sup> Interestingly, the intensity of antibodies with enzyme-linked immunosorbent assay is greater after starting dialysis therapy and then decreases with time on dialysis.



**Figure 1** Diagram showing changes in platelet counts and major clinical events during the course of the hospitalization. (A) Patient hospitalized with uremia and hypervolemia. (B) Cefoperazone + sulbactam discontinued. (C) Heparin-induced thrombocytopenia type II diagnosed and fondaparinux 1.5 mg/d started. (D) Fondaparinux and heparin-free hemodialysis continued. (E) Imipenem and vancomycin started due to sepsis. (F) Gastrointestinal bleeding developed and fondaparinux stopped. (G) Patient died due to sepsis and gastrointestinal bleeding.

Clinical trials have repeatedly demonstrated superior efficacy of fondaparinux over other anticoagulants as venous thromboembolism prophylaxis.<sup>13</sup> However, experience is limited regarding use of fondaparinux as a means of HD anticoagulation.<sup>14</sup> Sombolos et al.<sup>14</sup> showed that fondaparinux sodium at an intravenous dose of 2.5 mg can be used successfully as an anticoagulant during a 4-hour conventional HD session in patients dialyzed with low-flux polysulfone dialyzers.

Fondaparinux has also been used to treat and prevent thrombosis in case of HIT. Several case reports and series have described successful use of fondaparinux in HIT.<sup>7</sup> Fondaparinux was thought until recently not to cross-react with heparin-PF4 complexes. However, recent case reports showed the contrary.<sup>8,15,16</sup> Patients who were treated with fondaparinux developed type-II HIT.

Use of fondaparinux both as an HD anticoagulant and thromboprophylactic agent in HD patients has been reported only in three patients to date.<sup>10,11,17</sup> The half-life is markedly increased in patients with end-stage renal disease (ESRD). Thus, dose reduction either as 2.5 mg on alternate days or 0.2–0.5 mg/day is recommended. We used 1.5 mg/day both as a means of HD anticoagulation and thromboprophylaxis. We could not use lower doses because of repeated clot formations during HD sessions. Our patient did not experience a venous or arterial thrombotic event during the course of the treatment with fondaparinux. However, on the 70th day of hospitalization, he experienced an upper gastrointestinal hemorrhage manifesting with melena and hypotension. Initially increased platelet counts started to decrease this time possibly due

to severe sepsis. Although we lost our patient because of septic shock, fondaparinux effectively prevented development of any arterial and/or venous thrombosis. HD patients, especially in settings of acute dialysis, are at increased risk of hemorrhage. On the other hand, despite thrombocytopenia, patients with HIT are prone to paradoxical thromboembolic events.

In conclusion, we found fondaparinux effective in type-II HIT in our HD patient. Type-II HIT poses thrombotic threats to inflicted patients. Thus, anticoagulation with direct thrombin inhibitors must be used to prevent these untoward effects. Because we lacked direct thrombin inhibitors in our country, we used fondaparinux as the alternative anticoagulant agent in this patient. In contrast to patients without ESRD, HD patients have greater risk for hemorrhagic complications of anticoagulant agents. Caring physicians are under the heavy burden of balancing prevention of thrombosis with prevention of iatrogenic hemorrhage.

Manuscript received February 2012; revised April 2012.

## REFERENCES

- 1 Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. *Semin Thromb Hemost* 2004; **30**:273–283.
- 2 Otis SA, Zehnder JL. Heparin-induced thrombocytopenia: Current status and diagnostic challenges. *Am J Hematol* 2010; **85**:700–706.

- 3 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. *J Clin Invest* 1994; **93**:81–88.
- 4 Franchini M. Heparin-induced thrombocytopenia: An update. *Thromb J* 2005; **3**:14.
- 5 Chong BH, Gallus AS, Cade JF et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: A clinical outcome study. *Thromb Haemost* 2001; **86**:1170–1175.
- 6 Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation* 2001; **103**:1838–1843.
- 7 Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: A single-center experience. *Clin Appl Thromb Hemost* 2010; **16**:663–667.
- 8 Chong BH, Chong JJ. Heparin-induced thrombocytopenia associated with fondaparinux. *Clin Adv Hematol Oncol* 2010; **8**:63–65.
- 9 Matsuo T, Wanaka K. Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. *Clin Appl Thromb Hemost* 2008; **14**:459–464.
- 10 Wellborn-Kim JJ, Mitchell GA, Terneus WF, Jr. et al. Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. *Am J Health Syst Pharm* 2010; **67**:1075–1079.
- 11 Montagnac R, Brahimi S, Janian P, Melin JP, Bertocchio JP, Wynckel A. [Use of fondaparinux during hemodialysis in heparin-induced thrombocytopenia. About a new observation]. *Nephrol Ther* 2010; **6**:581–584.
- 12 Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. *Nephrol Dial Transplant* 2007; **22**:1680–1684.
- 13 Wade WE, Spruill WJ. Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. *Expert Rev Pharmacoecon Outcomes Res.* 2007; **7**:227–237.
- 14 Sombolos KI, Fragia TK, Gionanlis LC et al. Use of fondaparinux as an anticoagulant during hemodialysis: A preliminary study. *Int J Clin Pharmacol Ther* 2008; **46**:198–203.
- 15 Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. *Thromb Haemost* 2010; **104**:1071–1072.
- 16 Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia in a patient treated with fondaparinux. *Clin Adv Hematol Oncol* 2010; **8**:61–65.
- 17 Haase M, Bellomo R, Rocktaeschel J et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II. *Nephrol Dial Transplant* 2005; **20**:444–446.

---

## Testicular angina during hemodialysis: An unusual complication of ultrafiltration

Adrian SEQUEIRA,<sup>1</sup> Mary BUFFINGTON,<sup>1</sup> Xin GU,<sup>2</sup> Kenneth ABREO<sup>1</sup>

<sup>1</sup>Division of Nephrology and Hypertension, Department of Medicine, <sup>2</sup>Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA

### Abstract

During hemodialysis, the development of hypotension or symptoms suggestive of ischemia is used as a surrogate marker for the establishment of dry weight. These symptoms manifest commonly as muscle cramps, chest pain or abdominal pain. Hemodialysis patients are also prone to vascular calcification which may be medial or intimal. We report the case of a 68-year-old male who developed testicular pain while attempting to establish dry weight. Computerized tomography scan of his abdomen showed extensive vascular calcification. The end result in this case was bilateral orchiectomy. Histopathology revealed hyperplastic arteriosclerosis with intimal calcification contributing to ischemia.

**Key words:** Vascular, calcification, testicular, angina